Evidence map›Paper›PMID 40202714›Full record

ArticleJournal of nephrology2025

Comparative validation of the Mayo Clinic imaging classification and PROPKD score for predicting ADPKD progression across diverse ethnic cohorts.

Yasar Caliskan, Abdulmecit Yildiz, Hande Aypek, Ozgur A Oto, Cuma B Gul, Alparslan Demiray, Gulsah Cecener, Yigit Kurtulus, Bahar Bastani, Krista L Lentine and 1 more

Abstract readMulticenter StudyComparative StudyValidation Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yasar CaliskanDivision of Nephrology, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA. yasar.caliskan@health.slu.edu.ORCID http://orcid.org/0000-0003-3816-8047
Abdulmecit YildizDivision of Nephrology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Hande AypekDivision of Nephrology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Ozgur A OtoDivision of Nephrology, Istanbul University School of Medicine, Istanbul, Turkey.
Cuma B GulDivision of Nephrology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Alparslan DemirayDivision of Nephrology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Gulsah CecenerDivision of Medical Biology, Bursa Uludag University, Bursa, Turkey.
Yigit KurtulusDivision of Nephrology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Bahar BastaniDivision of Nephrology, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA.
Krista L LentineDivision of Nephrology, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA.
Ismail KocyigitDivision of Nephrology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutosomal dominant polycystic kidney disease (ADPKD) is a common cause of end-stage kidney disease (ESKD). In this retrospective multicenter cohort study, we aimed to evaluate the concordance, sensitivity and specificity of the predictive abilities of the Mayo Clinic Imaging Class (MCIC) and Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score for progression to ESKD.

methodsData for adult ADPKD patients of diverse ethnicities were obtained from 4 renal centers (Saint Louis, Kayseri, Bursa, Istanbul). The predictive value of MCIC and PROPKD was compared for progression to ESKD. ESKD was defined by the following criteria: (1) two consecutive estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73m

resultsOne hundred eighty-seven ADPKD patients with PKD1 or PKD2 variants were included, with the majority identifying as White (93%), followed by Black (6%) and Hispanic (0.5%). The PROPKD score showed moderate ability (AUC = 0.702) to predict progression to ESKD, performing better in Black patients (AUC = 0.800) than in White patients (AUC = 0.764). However, the predictive accuracy declined (AUC = 0.644) when the PROPKD score was categorized into risk levels (low, intermediate, high). The MCIC showed lower ability (AUC = 0.578) to predict progression to ESKD than the PROPKD score. Using LASSO regularization and multivariable Cox regression, self-identified Black ethnicity [HR = 12.24 (95% CI: 3.19-46.94, p < 0.001)] and age at initial follow-up [HR = 1.05 (95% CI:1.01-1.09, p = 0.007)] emerged as significant predictors of progression to ESKD.

conclusionsThe PROPKD score appears to be a useful tool for predicting ADPKD progression across various ethnic groups, with self-identified Black ethnicity and age at initial follow-up emerging as key predictors of kidney failure.

Indexed as

KidneyKidney Failure, ChronicPolycystic Kidney, Autosomal DominantAdultAgedDisease ProgressionFemaleGlomerular Filtration RateHumansMaleMiddle AgedPredictive Value of TestsReproducibility of ResultsRetrospective StudiesWhite PeopleGeneticsKidney failureMayo classificationPolycystic kidney diseasePROPKD score

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.